Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) CFO Elizabeth L. Hougen Sells 8,870 Shares of Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) CFO Elizabeth L. Hougen sold 8,870 shares of the business’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $32.81, for a total transaction of $291,024.70. Following the completion of the transaction, the chief financial officer now directly owns 107,885 shares of the company’s stock, valued at approximately $3,539,706.85. This represents a 7.60 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Ionis Pharmaceuticals Stock Down 2.6 %

Shares of Ionis Pharmaceuticals stock opened at $31.43 on Friday. Ionis Pharmaceuticals, Inc. has a twelve month low of $31.40 and a twelve month high of $52.49. The stock has a market cap of $4.96 billion, a price-to-earnings ratio of -12.88 and a beta of 0.35. The company has a current ratio of 8.91, a quick ratio of 8.82 and a debt-to-equity ratio of 1.86. The company has a fifty day moving average price of $35.63 and a 200 day moving average price of $41.17.

Institutional Investors Weigh In On Ionis Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Personalized Indexing Management LLC lifted its position in Ionis Pharmaceuticals by 3.5% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 7,624 shares of the company’s stock worth $363,000 after acquiring an additional 261 shares in the last quarter. Nicollet Investment Management Inc. raised its stake in shares of Ionis Pharmaceuticals by 1.5% during the third quarter. Nicollet Investment Management Inc. now owns 20,402 shares of the company’s stock valued at $817,000 after purchasing an additional 294 shares during the period. Amalgamated Bank lifted its position in shares of Ionis Pharmaceuticals by 3.1% during the third quarter. Amalgamated Bank now owns 9,957 shares of the company’s stock worth $399,000 after purchasing an additional 300 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Ionis Pharmaceuticals by 83.9% in the third quarter. GAMMA Investing LLC now owns 664 shares of the company’s stock valued at $27,000 after purchasing an additional 303 shares during the period. Finally, Itau Unibanco Holding S.A. grew its holdings in Ionis Pharmaceuticals by 40.9% during the 3rd quarter. Itau Unibanco Holding S.A. now owns 1,081 shares of the company’s stock valued at $43,000 after purchasing an additional 314 shares in the last quarter. Hedge funds and other institutional investors own 93.86% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on IONS shares. William Blair reaffirmed an “outperform” rating on shares of Ionis Pharmaceuticals in a research note on Friday, December 20th. StockNews.com downgraded Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, November 12th. Piper Sandler reduced their target price on Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating on the stock in a research report on Thursday, November 14th. Royal Bank of Canada restated an “outperform” rating and issued a $70.00 price target on shares of Ionis Pharmaceuticals in a report on Wednesday. Finally, Guggenheim cut their price objective on shares of Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating on the stock in a report on Wednesday, October 9th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $60.65.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.